The aim of this report is to assess the added benefit of fidaxomicin according to its approval for the following therapeutic indication: treatment of Clostridium difficile infections (CDI) also known as Clostridium difficile-associated diarrhoea (CDAD).
http://ift.tt/2ruBHkm
Πέμπτη 15 Ιουνίου 2017
Fidaxomicin -- Benefit Assessment According to §35a Social Code Book V [Internet].
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: September 2017 Source: Free Radical Biology and Medicine, Volume 110 Author(s): Lucía Fernández-del-Río, Anish Nag, Elen...
-
Abstract Noise pollution is a major factor of environmental complaints in many cities, which has significant impacts on human health. As a...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου